Lactoferrin-Anchored Tannylated Mesoporous Silica Nanomaterials for Enhanced Osteo-Differentiation Ability.

Sung Hyun Noh,Somang Choi,Hak-Jun Kim,Kyeongsoon Park,Han-Saem Jo,Hee Gyeong Song,Sung Eun Kim,Keung Nyun Kim

doi:10.3390/pharmaceutics13010030

Abstract

In the present study, we created lactoferrin-anchored mesoporous silica nanomaterials with absorbed tannic acid (LF/TA-MSNs) and evaluated the effect of these LF/TA-MSNs on the in vitro osteo-differentiation ability of adipose-derived stem cells (ADSCs) by testing alkaline phosphatase (ALP) level, calcium accumulation, and expression of osteo-differentiation-specific genes, including osteocalcin (OCN) and osteopontin (OPN). Both bare MSNs and LF/TA-MSNs exhibited round nano-particle structures. The LF/TA-MSNs demonstrated prolonged LF release for up to 28 days. Treatment of ADSCs with LF (50 μg)/TA-MSNs resulted in markedly higher ALP level and calcium accumulation compared to treatment with LF (10 μg)/TA-MSNs or bare MSNs. Furthermore, LF (50 μg)/TA-MSNs remarkably increased mRNA levels of osteo-differentiation-specific genes, including OCN and OPN, compared to MSNs or LF (10 μg)/TA-MSNs. Together, these data suggest that the ability of LF/TA-MSNs to enhance osteo-differentiation of ADSCs make them a possible nanovehicle for bone healing and bone regeneration in patients with bone defect or disease.

Highlights

Published: 26 December 2020Spinal fusion is an end-stage treatment to relieve the symptoms of lower-back pain by prohibiting motion in the affected segment [1]
When Tannic acid (TA)-mesoporous silica nanomaterials (MSNs) were further modified with different amounts of LF, the zeta potential values of LF/tannylated MSNs (TA-MSNs) increased depending on the amounts of LF, suggesting of 14 that the positively charged LF protein molecules were successfully modified on the 6surfaces of TA-MSNs
To analyze the late osteo-differentiation ability of adipose-derived stem cells (ADSCs) treated with MSNs, we investigated calcium accumulation

Summary

Introduction

Published: 26 December 2020Spinal fusion is an end-stage treatment to relieve the symptoms of lower-back pain by prohibiting motion in the affected segment [1]. IBGs have major disadvantages, such as pain at the donor site, nerve damage and inflammation, and prolonged surgical time, which limit their use in osteoporosis and metabolic diseases [5,6,7,8]. Allografts, acquired from either a cadaver or a living donor, come in one of three subtypes: fresh-frozen, freeze-dried, or demineralized bone matrix (DBM) [4]. Their use is limited by certain restrictions, such as lack of osteogenic properties, limited risk of hepatitis B virus (HBV) or HCV infection, and possible disease transmission [3,9,10]

Objectives

Methods

Results

Discussion

Conclusion